{
    "clinical_study": {
        "@rank": "51912", 
        "arm_group": [
            {
                "arm_group_label": "ASM-024", 
                "arm_group_type": "Experimental", 
                "description": "Dry Powder for Inhalation, b.i.d., 14 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dry Powder for Inhalation, b.i.d., 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, and clinical activity of\n      ASM-024 administered  as a dry powder for inhalation formulation to patients with GOLD 2 or\n      GOLD 3 COPD."
        }, 
        "brief_title": "Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase II, randomized, double-blind, placebo-controlled, two-way crossover study to\n      evaluate the safety, tolerability, and clinical activity of a new, dry powder for inhalation\n      formulation of ASM-024 administered twice daily for 14 days to patients with GOLD-2 or\n      GOLD-3 COPD."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female adult aged over 40 yrs with a clinically confirmed diagnosis of COPD\n             at the severity stages of GOLD 2 (moderate) or 3 (severe);\n\n          -  Stable COPD for 1 month prior to screening\n\n          -  Stable smoker for at least three months prior to screening, or non-smoker, with a\n             smoking history of \u2265 10 packs years;\n\n          -  FEV\u2081 \u2265 30 % and < 70 % of the predicted normal value;\n\n          -  Normal 12-lead ECG\n\n        Exclusion Criteria:\n\n          -  Clinically significant illness except COPD or surgery within 8 weeks prior to first\n             administration of the study medication;\n\n          -  Significant medical history that, in the Investigator's opinion, may adversely affect\n             participation;\n\n          -  History of allergy or significant adverse reaction to drugs similar to ASM-024, to\n             nicotine, or to cholinergic drugs or any drugs with a similar chemical structure;\n\n          -  History of hypersensitivity (anaphylaxis, angioedema) to any drug;\n\n          -  Positive pregnancy test for female subjects;\n\n          -  Use of medications known to prolong QT/QTc interval;\n\n          -  Clinically significant 12 lead ECG at screening;\n\n          -  Clinically significant physical examination or laboratory findings or abnormal vital\n             signs;\n\n          -  History of alcohol or drug abuse;\n\n          -  Positive hepatitis B or C or HIV test at Screening;\n\n          -  Investigational drug within 30 days of Screening; long-acting investigational drug\n             within 90 days of screening;\n\n          -  Previous exposure to ASM-024; and\n\n          -  Women of child-bearing potential and male participants unwilling or unable to use\n             accepted methods of birth control."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855230", 
            "org_study_id": "ASM-024/II/STA-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASM-024", 
                "description": "ASM-024 b.i.d for 14 days", 
                "intervention_name": "ASM-024", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo b.i.d. for 14 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 21, 2014", 
        "location": {
            "contact": {
                "email": "marie-josee.breton@criucpq.ulaval.ca", 
                "last_name": "Marie-Jos\u00e9e Breton, B.SC. N.", 
                "phone": "418-656-8711", 
                "phone_ext": "5823"
            }, 
            "facility": {
                "address": {
                    "city": "Quebec", 
                    "country": "Canada", 
                    "zip": "G1V 4G5"
                }, 
                "name": "Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec"
            }, 
            "investigator": {
                "last_name": "Fran\u00e7ois Maltais, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Two-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Dry Power Inhalation to Patients With GOLD 2 (Moderate) or GOLD 3 (Severe) Chronic Obstructive Pulmonary Disease (COPD)", 
        "other_outcome": {
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Physical examination: Day 14; vital signs: Days 1, 2, 3, & 14; 12-lead ECG: Days 1, 2, 3, & 14; AEs: from Day 1 to patient's final study visit; clinical laboratory evaluations: Day 14"
        }, 
        "overall_contact": {
            "email": "marie-josee.breton@criucpq.ulaval.ca", 
            "last_name": "Marie-Jos\u00e9e Breton, B.Sc. N.", 
            "phone": "418-656-8711", 
            "phone_ext": "5823"
        }, 
        "overall_official": {
            "affiliation": "Asmacure Lt\u00e9e", 
            "last_name": "Yvon Cormier, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "FEV\u2081 AUC  (0 -6 h)", 
            "safety_issue": "No", 
            "time_frame": "Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855230"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in Residual Volume (RV)", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, & 14"
            }, 
            {
                "measure": "Peak change in FEV\u2081", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, & 14"
            }, 
            {
                "measure": "Change from baseline in Inspiratory Capacity (IC)", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, & 14"
            }, 
            {
                "measure": "Change from baseline in Functional Residual Capacity (FRC)", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, &14"
            }, 
            {
                "measure": "Change from baseline in FEV\u2081", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "measure": "Change from baseline in FEV\u2081/FVC", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, & 14"
            }, 
            {
                "measure": "FVC AUC (0-6 h)", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, & 14"
            }, 
            {
                "measure": "Use of rescue medication", 
                "safety_issue": "No", 
                "time_frame": "From Day 1 to Day 14"
            }
        ], 
        "source": "Asmacure Lt\u00e9e", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asmacure Lt\u00e9e", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}